The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m 2 in Spain

Author： Fonseca Tiago  

Publisher： Informa Healthcare

ISSN： 1369-6998

Source： Journal of Medical Economics, Vol.16, Iss.7, 2013-07, pp. : 926-938

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 71, Iss. 12, 2017-12 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

All‐cause and diabetes‐related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 672-680

John Wiley & Sons Inc

Access to resources Recommend Favorite

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

By Ray Joshua A.   Boye Kristina S.   Yurgin Nicole   Valentine William J.   Roze Stéphane   McKendrick Jan   Tucker Daniel M. D.   Foos Volker   Palmer Andrew J.  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 609-622

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite